Insulin resistance, oxidative stress and cardiovascular complications: Role of sirtuins

Current Pharmaceutical Design

Volumn 19, Issue 32, 2013, Pages 5663-5677

  Bagul, Pankaj K ^a   Banerjee, Sanjay K ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Acetylation; Cardiovascular complications; Diabetes; Insulin resistance; Mitochondria; Oxidative stress; SIRT; Sirtuins

Indexed keywords

HISTONE; NONHISTONE PROTEIN; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7;

BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR SYSTEM; CELL ORGANELLE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; EPIGENETICS; HUMAN; INSULIN RESISTANCE; LIFESTYLE; MEDICAL LITERATURE; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; INSULIN; INSULIN RESISTANCE; LIFE STYLE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SIRTUINS;

EID: 84884230262     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990372     Document Type: Review

References (222)

1. David RW, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-21.
2. Brownlee M. Biology of diabetic complications. Nature 2001; 414: 813-20.
3. Mehra NK, Kumar N, Kaur G, Kanga U, Tandon N. Biomarkers of susceptibility to type 1 diabetes with special reference to the Indian population. Indian J Med Res 2007; 321-44.
4. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes? Curr Pharm Des 2010; 16(34): 3939-47.
5. Kahan SE. The relative contributions of insulin resistance and betacell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
6. Afanas'ev I. Signaling of reactive oxygen and nitrogen species in diabetes mellitus. Oxid Med Cell Longev 2010; 3(6): 361-73.
7. Boudina S. Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-23.
8. Di Bonito P, Moio N, Cavuto L, et al. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 2005; 22: 1720-25
9. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008; 51(2): 27-9.
10. Wägner AM, Cloos P, Bergholdt R, et al. Post-translational protein modifications in type 1 diabetes: role for the repair enzyme protein-L-isoaspartate (D-aspartate) O-methyltransferase? Diabetologia 2007; 50(3): 676-81.
11. Christopher TW, Tsodikova GS, Gatto GJ, Chemie A. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew. Chem. Int. Ed 2005; 44: 7342-72.
12. Pirola L, Zerzaihi O, Vidal H, Solari F. Protein acetylation mechanisms in the regulation of insulin and insulin-like growth factor 1 signalling. Mol Cell Endocrinol.2012; 1-10.
13. Han SH. Potential role of sirtuin as a therapeutic target for neurodegenerative diseases. J Clin Neurol 2009; 5(3): 120-5.
14. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2009; 7: 841-54.
15. Yu J, Auwerx J. The role of sirtuins in the control of metabolic homeostasis. Ann N Y Acad Sci 2009; 19: 10-9.
16. Chakrabarty SP, Balaram H, Chandrasekaran S. Sirtuins: Multifaceted Drug Targets. Current Molecular Medicine 2011; 11(9): 709-18.
17. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and non-conserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005; 16: 4623-35.
18. Oberdoerffer P, Sinclair DA. The role of nuclear architecture in genomic instability and ageing. Nat Rev Mol Cell Biol 2007; 8: 692-702.
19. Westphal CH, Dipp MA, Guarente L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci 2007; 32: 555-60.
20. Yamamoto H, Schoonjans K, Auwerx J. Sirtuin functions in health and disease. Mol Endocrinol 2007; 21: 1745-55.
21. Haigis MC, Guarente LP. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20(21): 2913-21.
22. Chalkiadaki A, Guarente L. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol 2012; 8(5): 287-96.
23. Nakagawa T, Guarente L. Sirtuins at a glance, J Cell Sci 2011; 124: 833-8.
24. Wang J, Chen J. SIRT1 regulates auto acetylation and histone acetyltransferase activity of TIP60. J Bio Chem 2010; 285 (15): 11458-11464.
25. Langley E, Pearson M, Faretta M, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO 2002; 21 (10): 2383-96.
26. Daitoku H, Hatta M, Matsuzaki H, et al. Silent information regulator 2 potentiates Foxo 1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci 2004; 101(27): 10042-7.
27. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO 2005; 24(5): 1021-32.
28. Cardellini M, Menghini R, Martelli E, et al. TIMP3 Is Reduced in Atherosclerotic Plaques From Subjects With Type 2 Diabetes and Increased by SIRT1. Diabetes 2009; 58(10): 2396-401.
29. Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116(4): 551-63.
30. Luo J, Nikolaev AY, Imai SI, et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 2001; 107(2): 137-48.
31. Bae NS, Swanson MJ, Vassilev A, Howard BH. Human histone deacetylase SIRT2 interacts with the homeobox transcription factor HOXA10. J Bio 2004; 135(6): 695-700.
32. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci 2006; 103(27): 10224-9.
33. Chen YR, Fang SR, Fu YC, Zhou XH, Xu MY, Xu WC. Calorie restriction on insulin resistance and expression of SIRT1 and SIRT4 in rats. Biochem Cell Biol 2010; 88(4): 715-22.
34. Patel JH, Du Y, Ard PG, et al. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Bio 2004; 24: 10826-34.
35. Milner J. Cellular regulation of SIRT1. Curr Pharm Des 2009; 15(1): 39-44.
36. Srivastava S, Haigis MC. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer's and Parkinson's diseases. Curr Pharm Des 2011; 17(31): 3418-33.
37. Carafa V, Nebbioso A, Altucci L. Sirtuins and disease: the road ahead. Front Pharmacol. 2012; 3: 1-6.
38. Uciechowska U, Sippl W, Jung M. NAD 1-dependent histone deacetylases (sirtuins) as novel therapeutictargets. Med Res Rev 2009; 30(6): 861-89.
39. Lin S. Sirtuins. Biochim Biophys Acta 2010; 1804: 1565-6.
40. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 2003; 11: 437-44.
41. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421-6.
42. Burgering BM, Kops GJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci 2002; 27: 352-60.
43. Greer E, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005; 24: 7410-25.
44. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell 2005; 120: 449-60.
45. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtuins. Annu Rev Biochem 2006; 75: 435-65
46. Prozorovski T, Topphoff SU, Glumm R, et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat. Cell Biol 2008; 10: 385-94.
47. Sablina AA, Budanov AV, Ilyinskaya GV, et al. The antioxidant functions of the p53 tumor suppressor. Nat. Med 2005; 11: 1306-13.
48. Liu D, Xu Y. p53, oxidative stress and aging. Antioxid Redox Signal 2011; 15(6): 1669-78.
49. Han MK, Song EK, Guo Y, Ou X, Mantel C, Broxmeyer HE. SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2008; 2: 241-51.
50. Vaziri H, Dessain SK, Ng EE, et al. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-59.
51. Cao C, Lu S, Kivlin R, Wallin B, Card E, Bagdasarian A, et al. SIRT1 confers protection against UVB and H2O2-induced cell death via modulation of p53 and JNK in cultured skin keratinocytes. J Cell Mol Med 2009; 13(9B): 3632-43.
52. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu YS, Patel P, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci 2003; 100(19): 10794-9.
53. Kume S, Haneda M, Kanasaki K. et al. Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic. Biol. Med 2006; 40: 2175-82.
54. Wang C, Chen L, Hou X, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 2006; 8(9): 1025-31.
55. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-5.
56. Wang F, Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 2007; 6: 505-14.
57. Maiese K, Chong ZZ, Shang YC, Hou J. A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev 2009; 29: 395-418.
58. Hasegawa K, Wakino S, Yoshioka K, et al. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun 2008; 372: 51-6.
59. Hou J, Wang S, Shang YC, et al. Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res 2011; 8: 220-35.
60. Kops GJ, Dansen TB, Polderman PE, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002; 419: 316-21.
61. Alcendor RR, Gao S, Zhai P, et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007; 100: 1512-21
62. Hariharan N, Maejima Y, Nakae J, et al. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ Res 2010; 107: 1470-82.
63. Xiong S, Salazar G, Patrushev N, Alexander RW. FoxO1 mediates an auto feedback loop regulating SIRT1 expression. J Biol Chem 2011; 286: 5289-99.
64. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead dependent pathway. Science 2004; 306: 2105-8.
65. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a dependent antioxidant defense mechanisms in mice. J. Clin. Invest 2009; 119: 2758-71.
66. Jacobs KM, Pennington JD, Bisht KS, et al. SIRT3 interacts with the daf-16 homolog FOXO3a in themitochondria, as well as increases FOXO3a dependent gene expression. Int. J. Biol. Sci 2008; 4: 291-9.
67. Pialoux V, Mounier R, Brown AD, Steinback CD, Rawling JM, Poulin MJ. Relationship between oxidative stress and HIF-1 alpha mRNA during sustained hypoxia in humans. Free Radic Biol Med 2009; 46(2): 321-6.
68. Dioum EM, Chen R, Alexander MS, et al. Regulation of hypoxiainducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 2009; 324: 1289-93.
69. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxiainducible factor 1alpha. Mol. Cell 38: 864-878; 2010.
70. Zhong L, D'Urso A, Toiber D, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010; 140: 280-93.
71. Mariappan N, Elks CM, Sriramula S, et al. NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc res 2010; 85(3): 473-83.
72. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-jBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO 2004; 23(12): 2369-80.
73. Rothgiesser KM, Erener S, Waibel S, Lüscher B, Hottiger MO. SIRT2 regulates NF-kB-dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 2010; 123: 4251-8.
74. Gioacchino N, When Sirtuins and NF-κB Collide. Cell 2009; 136: 19-21.
75. Clementi E, Nisoli E. Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism. Comp Biochem Physiol A Mol Integr Physiol 2005; 142: 102-10.
76. Mattagajasingh I, Kim CS, Naqvi A, et al. SIRT1 promotes endothelium-dependent vascu-lar relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci 2007; 104: 14855-60.
77. Yumiko K, LaKisha G, Melanie T, Jianqi Y, Ifeanyi JA. Acetylation-Deacetylation of the Transcription Factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its Transcriptional Activity and Nucleo-cytoplasmic Localization. J Biol Chem 2011; 286(9): 7629-40.
78. Bagul PK, Middela H, Matapally S, et al. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 2012; 66: 260-8.
79. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460(7255): 587-91.
80. Gan L, Mucke L. Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 2008; 58 (1):10-4.
81. Hu Y, Mivechi NF. HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo. J Biol Chem 2003; 278: 17299-306.
82. Westerheide SD, Anckar J, Stevens SM Jr, Sistonen L, Morimoto RI. Stress inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 2009; 323: 1063-6
83. Rathaus M, Lerrer B, Cohen HY. DeubiKuitylation: a novel DUB enzymatic activity for the DNA repair protein, Ku70. Cell Cycle 2009; 8: 1843-52.
84. Cohen HY, Miller C, Bitterman KJ, et al, Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-2.
85. Li Li, Gao P, Zhang H. SIRT1 inhibits angiotensin II-induced vascular smooth muscle cell hypertrophy. Acta Biochim Biophys Sin 2011, 43: 103-9
86. Uribarri J, Cai W, Ramdas M. Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes Potential role of AGER1 and SIRT1. Diabetes Care July 2011; 34: 1610-6.
87. Zhao S, Xu W, Jiang W et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010; 327: 1000-4.
88. Lombard D, Alt W, Cheng L, et al. Mammalian Sir2 homolog SIRT3 regulates global mito-chondrial lysine acetylation. Mol Cell Biol 2007; 27: 8807-14.
89. Jacobs KM, Gius D. Superoxide levels and mitochondrial function are regulated by SIRT3. Free Radic Biol Med 2007; 43: S156.
90. Bao J, Scott I, Lu Z, et al. SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity. Free Radic. Biol. Med 2010; 49: 1230-7.
91. Ahn BH, Kim HS, Song S, et al. Role for the mitochondrial deacetylase Sirt3in regulating energy homeostasis. Proc. Natl. Acad. Sci 2008; 105: 14447-52.
92. Cimen H, Han MJ, Yang Y, Tong Q, Koc H, Koc EC. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry 2010; 49: 304-11.
93. Shimazu T, Hirschey D, Hua L, et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab 2010; 12: 654-61.
94. Yi W, Fu P, Fan Z, et al. Mitochondrial HMG-CoA synthase partially contributes to antioxidant protection in the kidney of strokeprone spontaneously hypertensive rats. Nutrition 2010; 26: 1176-80.
95. Finley W, Haas W, Desquiret-Dumas V, et al. Succinate dehydrogenase is a direct target of sirtuin 3 531 deacetylase activity. PLoS 2011; 6: e23295.
96. Bell E, Emerling M, Ricoult S, Guarente L. SirT3 suppresses hypoxia 497 inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS pro-498 duction. Oncogene 2011; 30: 2986-96.
97. Jing E, Emanuelli B, Hirschey M, et al. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production PNAS 2011; 108: 14608-13.
98. Hafner V, Dai J, Gomes A, et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging 2010; 2: 914-23.
99. Wada K, Okunuki K. Studies on chemically modified Cytochrome cI. The Acetylated Cytochrome c J Biochem 1968; 64: 667-87.
100. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol 2008; 382: 790-801.
101. Tong S, Wang F, Stieren E, Tong Q. SIRT3, a Mitochondrial Sirtuin Deacetylase, Regulates Mitochondrial Function and Thermogenesis in Brown Adipocytes. The J Bio Chem 2005; 280: 13560-7.
102. Kong X, Wang R, Xue Y, et al. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 2010; 5: e11707.
103. de Keizer L, Burgering M, Dansen B. Forkhead box O as a sensor, mediator, and regulator of redox signaling. Antioxid. Redox Signal 2011; 14: 1093-106.
104. Palacios M, Carmona J, Michan S, et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging 2009; 1: 771-83.
105. Someya S, Yu W, Hallows WC, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010; 143: 802-12.
106. Kim HS, Patel K, Muldoon JK, et al. SIRT3 is a mitochondrialocalized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010; 17(1): 41-52.
107. Kim SC, Sprung R, Chen Y, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006; 23: 607-18.
108. Qiu, X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3 mediated SOD2 activation. Cell Metab 2010; 12: 662-7.
109. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and coregulates major cellular functions. Science 2009; 325: 834-40.
110. Tao R, Coleman MC, Pennington JD, et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine-122 regulates MnSOD activity in response to stress. Mol Cell 2010; 40: 893-904.
111. Chen Y, Zhang J, Lin Y, et al. Tumor suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep 2011; 12: 534-41.
112. Webster BR, Lu Z, Sack MN, Scott I. The role of sirtuins in modulating redox stressors. Free Radic Biol Med 2012; 52(2): 281-90.
113. Kong X, Wang R, Xue Y. Sirtuin 3, a New Target of PGC-1a, Plays an Important Role in the Suppression of ROS and Mitochondrial Biogenesis. PLoS ONE 2010; 5(7): e11707
114. Haigis MC, Mostoslavsky R, Haigis KM, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006; 126: 941-54.
115. Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009; 137: 560-70.
116. Hallows WC, Yu W, Smith BC, et al. Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol. Cell 2011; 41: 139-49.
117. Zhiyong M, Christopher H, Xiao T, et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science 2011; 332: 1443-6.
118. Olesya V, Christian S, Praveen G, et al. Sirt7 Increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 2008; 102: 703-10.
119. Kim SP, Catalano KJ, Hsu IR, Chiu J, Richey JM, Bergman RN. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. Am J Physiol Endocrinol Metab 2007; 292: E1590-8.
120. Saini V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes 2010; 1(3): 68-75.
121. Bordone L, Motta MC, Picard F et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006; 4: e31.
122. Kitamura YI, Kitamura T, Kruse JP, et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell. Metab 2005; 2: 153-63.
123. Ramsey KM, Mills KF, Satoh A, Imai S. Age-associated loss of sirt1-mediated enhancement of glucose stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BesTO) mice. Aging Cell 2008; 7: 78-88.
124. Moynihan KA, Grimm AA, Plueger MM, et al. Increased dosage of mammalian sir2 in pancreatic beta cells enhances glucosestimulated insulin secretion in mice. Cell Metab 2005; 2: 105-17.
125. Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell. Metab 2007; 6: 307-19.
126. Seely BL, Staubs PA, Reichart DR, et al. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 1996; 45: 1379-85.
127. Goldstein BJ, Kowalczyk AB, White MF, Harbeck M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem 2000; 275: 4283-9.
128. Inoue G, Cheatham B, Emkey R. Kahn CR. Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2. J Biol Chem 1998: 273: 11548-55.
129. Zhang J. The direct involvement of SIRT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem 2007; 282: 34356-64.
130. Yoshizaki T, Milne JC, Imamura T, et al. SIRT 1 exerts antiinflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009; 29: 1363-74.
131. McGarry JD. Banting, Dysregulation of fatty acid me in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
132. Dobbins RL, Szczepaniak LS, Bentley B, Esser V, Myhill J, McGarry JD. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 2001; 50: 123-30.
133. Lam TK, Carpentier A, Lewis GF, van de WG, Fantus IG, Giacca A. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003; 284: E863-73.
134. Shulman GI. Cellular mechanisms of insulin resistance. J. Clin. Invest 2000; 106: 171-6.
135. Falholt K, Jensen I, Lindkaer JS, et al. Carbohydrate and lipid metabolism of skeletal muscle in type 2 diabetic patients. Diabet Med 1988; 5: 27-31.
136. Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46: 983-8.
137. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999; 276: E977-89.
138. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis 2001; 21(1): 3-16.
139. Gupta G, Cases JA, She L, et al. Ability of insulin to modulate hepatic glucose production aging rats is impaired by fat accumulation. Am J Physiol Endocrinol Metab 2000; 278: E985-91.
140. Man ZW, Hirashima T, Mori, S, Kawano K. Decrease in triglyceride accumulation in tissues by restricted diet and improvement of diabetes in O Long-Evans Tokushima fatty rats, a non-insulindependent diabetes model. Metabolism 2000; 49: 108-14.
141. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749-58.
142. Sasagawa T, Ishii K, Hasuda K, Kubota M, Ota Y, Okita M. The effect of dietary polyunsaturated fatty acid on insulin sensitivity and lipid metabolism in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Prostaglandins Leukot. Essent Fatty Acids 2001; 64: 181-7.
143. Lindroos SA, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-8.
144. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16(17): 1941-51.
145. Picard F, Kurtev M, Chung N, et al. SIRT 1 promotes fat mobilization in white adipocytes by repressing PPARγ. Nature 2004; 429: 771-6.
146. Wang H, Qiang L, Farmer SR. Identification of a domain within peroxisome proliferator activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 2008; 28: 188-200.
147. Dowell P, Otto TC, Adi S, Lane MD. Convergence of peroxisome proliferator activated receptor gamma and Foxo1 signaling pathways. J Biol Chem 2003; 278: 45485-491.
148. Subauste AR, Burant CF. Role of FoxO1 in FFA-induced oxidative stress in adipocytes. Am J Physiol Endocrinol Metab 2007; 293: e159-64.
149. Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1 C/enhancer binding protein alpha transcriptional complex. J Biol Chem 2006; 281: 39915-24.
150. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 2005; 434: 113-8.
151. Rui HW, Kim HS, Xiao C, Xu X, Gavrilova O, Deng C. Hepatic SIRT1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance, J Clin Invest 2011; 121(11): 4477-90.
152. Hou X, Xu S, Maitland-Toolan KA, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008; 283: 20015-26.
153. Fulco M, Schiltz RL, Iezzi S, King MT, et al. SIR2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell 2003; 12: 51-62.
154. Bouras T, Fu M, Sauve AA, et al. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem 2005; 280: 10264-76.
155. Michael LF, Wu Z, Cheatham RB, et al. Restoration of insulin sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcription coactivator PGC-1. Proc. Natl Acad Sci 2001; 98: 3820-5.
156. Gerhart-Hines Z, Rodgers JT, Bare O, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1 alpha. EMBO 2007; 26(7): 1913-23.
157. Li Y, Xu S, Giles A, Nakamura K. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J 2011; 25: 1664-79.
158. Jung TW, Lee KT, Lee MW, Ka KH. SIRT1 attenuates palmitateinduced endoplasmic reticulum stress and insulin resistance in HepG2 cells via induction of oxygen-regulated protein 150. Biochem Biophys Res Commun 2012; 422: 229-32.
159. Wang F, Tong Q. SIRT2 Suppresses Adipocyte Differentiation by Deacetylating FOXO1 and Enhancing FOXO1's Repressive Interaction with PPAR-γ, Mol Bio Cell 2009; 20: 801-8.
160. Jinga E, Emanuellia B, Hirscheyb MD, et al. Sirtuin-3 (SIRT3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Natl Acad Sci, 2011; 108(35): 14608-13.
161. Hirschey MD, Shimazu T, Jing E, et al. SIRT3 Deficiency and Mitochondrial Protein Hyperacetylation Accelerate the Development of the Metabolic Syndrome, Molecular Cell 2011; 44: 1-14.
162. Nasrin N, Wu X, Fortier E, et al. SIRT4 Regulates Fatty Acid Oxidation and Mitochondrial Gene Expression in Liver and Muscle Cells. J Bio Chem 2010; 285(42): 31995-2002
163. Argmann C, Auwerx J. Insulin secretion: SIRT4 gets in on the act. Cell 2006; 126(5): 837-9.
164. Ahuja N, Schwer B, Carobbio S, et al. Regulation Of Insulin Secretion By Sirt4, A Mitochondrial ADP-Ribosyltransferase, J Bio Chem 2007; 282: 33583-92.
165. Xiao C, Kim HS, Lahusen T, SIRT6 Deficiency Results in Severe Hypoglycemia by Enhancing Both Basal and Insulin-stimulated Glucose Uptake in Mice. JBiol Chem 2010; 285(47): 36776-84.
166. Kanfi Y, Naiman S, Amir G, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012; 05: 3-6.
167. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995; 44: 369-74.
168. Maddux BA, See W, Lawrence JC, Goldfine AL, Goldfine ID, Evans JL. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micro molar concentrations of lipoic acid. Diabetes 2001; 50: 404-10.
169. Tretter L, Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of alpha-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci 2000; 20: 8972-79.
170. Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N. Pro-longed oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 1998; 47: 1562-9.
171. Talior I, Yarkoni M, Bashan N, Fielman EH. Increased glucose uptake promotes oxidative stress and PKC delta activation in adipocytes of obese, insulin-resistant mice. Am J Physiol 2003; 285: E295-302.
172. Jacob S, Ruus P, Hermann R, et al. Oral administration of RACalpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999; 27: 309-14.
173. Jacob S, Streeper RS, Fogt DL, et al. The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in insulinresistant rat skeletal muscle. Diabetes 1996; 45: 1024-1029.
174. Midaoui A, Champlain J. Prevention of hypertension, insulin resistance and oxidative stress by a-lipoic acid. Hypertension 2002; 39: 303-7.
175. Wu R, Lamontagne D, Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 2002; 105: 387-92.
176. Midaoui A, Wu R, Champlain J. Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. J Hypertens 2002; 20: 1407-12.
177. Su H, Hung L, Chen J. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2006; 290: E1339-46.
178. Paolisso, G., Giugliano, D. Oxidative stress and insulin action. Is there a relationship? Diabetologia 1996; 39: 357-63.
179. Ceriello, A. New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care 2003; 26: 1589-96.
180. Sironi AM, Sicari R, Folli F, Gastaldelli A. Ectopic fat storage, insulin resistance, and hypertension. Curr Pharm Des 2011; 17(28): 3074-80.
181. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996; 25: 255-70.
182. Fenner E, King GL, Vascular dysfunction in diabetes mellitus. Lancet 1997; 350 (1): 9-13.
183. Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993; 23(1): 118-26.
184. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism 1995; 44: 363-8.
185. Maxwell SRJ, Thomason H, Sandler D et al. Antioxidant status in patients with uncomplicated insulin-dependent and noninsulindependent diabetes mellitus. Eur J Clin Invest 1997; 27: 484-90.
186. Zadeh NJ, Sarmadi TJ, Mccarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995; 44: 1054-8.
187. Zadeh NJ, Rahimi A, Sarmadi TJ. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 1997; 40: 647-53.
188. Sundaram RK, Bhaskar A, Vijayalingam S, Viswanathan M, Mohan R, Shanmugasundaram KR. Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin Sci 1996; 90: 255-60.
189. Tesfamariam B Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994; 16: 383-91.
190. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant lipoic acid. A 3-week multicenter randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-33.
191. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-κB activation in late diabetic complications. Biofactors 1999; 10: 157-67.
192. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des 2008; 14(10): 987-9.
193. Cohen P. Dissection of protein kinase cascades that mediate cellular response to cytokines and cellular stress. Adv Pharmacol 1996; 36: 15-27.
194. Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 1996; 271: 24313-6.
195. Adler V, Yin Z, Tew KD, Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999; 18: 6104-11.
196. Busserolles J, Gueux E, Rock E, Demigne C, Mazur A, Rayssiguier Y. Oligofructose protects against the hypertriglyceridemia and prooxidative effects of a high fructose diet in rats. J Nutr 2003; 133: 1903-8.
197. Nandhini AT, Thirunavukkarasu V, Ravichandran MK, Anuradha CV. Effect of taurine on biomarkers of oxidative stress in tissues of fructose-fed insulin-resistant rats. SingaporeMed. J 2005; 46: 82-7.
198. Diniz YS, Santos PP, Assalin HB, et al. Conjugated linoleic acid and car-diac health: Oxidative stress and energetic metabolism in standard and sucrose-rich diets. Eur. J. Pharmacol 2008; 579: 318-25.
199. Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Cardiac lipids and antioxidant status in high fructose rats and the effect of alpha-lipoic acid. Nutr Metab Cardiovasc Dis 2004; 14: 351-7.
200. Shirpoor A, Salami S, Khadem-Ansari MH, Ilkhanizadeh B, Pakdel FG, Khademvatani K. Cardioprotective effect of vitamin E: Rescues of diabetes induced cardiac malfunction, oxidative stress, and apoptosis in rat. J Diabetes Complications 2009; 23: 310-6.
201. Coetzee IH, Lochner A. Free radical effects on myocardial membrane microviscosity. Cardioscience 1993; 4: 205-15.
202. Hool LC, Arthur PG. Decreasing cellular hydrogen peroxide with cata-lase mimics the effects of hypoxia on the sensitivity of the Ltype Ca2+ channel to beta-adrenergic receptor stimulation in cardiac myocytes. Circ Res 2002; 91: 601-9.
203. Hudasek K, Brown ST, Fearon IM. H2O2 regulates recombinant Ca2+ channel alpha1C subunits but does not mediate their sensitivity to acute hypoxia. Biochem. Biophys. Res. Commun 2004; 318: 135-41.
204. Kowluru RA, Engerman RL, Kern TS. Diabetes-induced metabolic abnormalities in myocardium: Effect of antioxidant therapy. Free Radic Res 2000; 32: 67-74.
205. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol Physiol 2000; 279: L1005-28.
206. Tomomi I, Hisojuki J. Oxygen free radicals in the failing myocardium. Circulation Res 1999; 85: 357-63
207. Bassege E, Sommer O, Schwemmar M, Bunger R. Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species. Am J Physiol 2000; 279: H2431-8.
208. Tomomi I, Tsutsui H, Kingugaw S. Direct evidence of increased hydroxyl radical in the failing myocardium. Circ Res 2000; 186: 152-7.
209. Barsotti A, Giannoni A, Di Napoli P, Emdin M. Energy metabolism in the normal and in the diabetic heart. Curr Pharm Des 2009; 15(8): 836-40.
210. Vitale C, Collin P. Optimization of cardiac metabolism in diabetes mellitus. Curr Pharm Des 2008; 14(25): 2537-50.
211. Hunter SJ, Garvey WT. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med 1998; 105: 331-45.
212. Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 1994; 123: 647-52.
213. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-81.
214. Potenza MA, Montagnani M. Abnormal insulin signaling: early detection of silent coronary artery disease erectile dysfunction? Curr Pharm Des 2008; 14(35): 3737-48.
215. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11(18): 2279-99.
216. Hill DJ, Milner RD. Insulin as a growth factor. Pediatr Res 1985; 19: 879-86.
217. Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993; 87: 1715-21.
218. Ren J, Pulakat L, Whaley-Connell A, Sowers JR. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med 2010; 88: 993-1001.
219. Przyklenk K, Kloner RA. Superoxide dismutase plus catalase improve contractile function in the canine model of the "stunned myocardium". Circ Res 1986; 58: 148-56.
220. Dong F, Fang CX, Yang X, Zhang X, Lopez FL, Ren J. Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: Role of oxidative stress, protein carbonyl formation and insulin sensitivity. Diabetologia 2006; 49: 1421-33.
221. +, Sirtuins, and Cardiovascular Disease. Curr Pharm Des 2009; 519: 110-7.
222. Schug TT, Li X. Surprising sirtuin crosstalk in the heart. Aging 2010; 2(3): 129-32.